Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Lipson (Wynnewood, United States of America). LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again?. International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose

Member's Comments

No comment yet.

Related content which might interest you: INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 The inhaled corticosteroid/long-acting ß-agonist maintenance and reliever therapy regimen: where to from here? Source: Eur Respir J, 51 (1) 1702338; 10.1183/13993003.02338-2017 Year: 2018 Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016 Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003 Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010 Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020 Year: 2021 Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2010 - Management of airway disease Year: 2010 Efficacy of montelukast as complementary therapy to fixed association ICS/LABA in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Budesonide/formoterol maintenance and reliever therapy compared with conventional best standard treatment Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008 Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018